• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Oculis Holding AG

    10/31/25 4:55:55 PM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OCS alert in real time by email
    6-K 1 d66396d6k.htm 6-K 6-K
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 6-K

     

     

    REPORT OF FOREIGN ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16

    OF THE SECURITIES EXCHANGE ACT OF 1934

    For the Month of October 2025

    (Commission File No. 001-41636)

     

     

    Oculis Holding AG

    (Translation of registrant’s name into English)

     

     

    Bahnhofstrasse 20

    CH-6300

    Zug, Switzerland

    (Address of registrant’s principal executive office)

     

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

    Form 20-F ☒   Form 40-F ☐

     

     
     


    INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

    On October 29, 2025, Oculis Holding AG (the “Company”) entered into the following agreements in connection with offerings of an aggregate of 5,432,098 of its ordinary shares, CHF 0.01 nominal value per share, at an offering price of $20.25 per share: (i) an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, Leerink Partners LLC and Pareto Securities AB, as representatives of the several underwriters named therein (collectively, the “Underwriters”), in connection with the offering and sale by the Company in an underwritten offering of 4,691,358 ordinary shares (the “Underwritten Offering”) and (ii) a subscription agreement (the “Subscription Agreement”) with an investor relating to a registered direct offering (the “Direct Offering” and, together with the Underwritten Offering, the “Offerings”) of 740,740 ordinary shares. In addition, the Underwriting Agreement provides the Underwriters in the Underwritten Offering a 30-day option to purchase up to an additional 703,703 ordinary shares from the Company at $20.25 per share, less underwriting discounts and commissions.

    The gross proceeds from the Offerings will be approximately $110.0 million, before deducting underwriting commissions and estimated offering expenses payable by the Company, or $124.2 million if the Underwriters exercise this option to purchase additional ordinary shares in full. The Offerings are expected to close on or about November 3, 2025, subject to customary closing conditions. The Company believes that the net proceeds from the Offerings, together with its existing cash, cash equivalents and short-term investments, will be sufficient to enable the Company to fund operations to late 2028.

    The Offerings were made pursuant to the Company’s effective registration statement on Form F-3 (File No. 333-278409) filed with the Securities and Exchange Commission on April 1, 2024.

    The Underwriting Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the Underwriters, including for liabilities under the Securities Act of 1933, as amended, and other obligations of the parties, and termination provisions. The Subscription Agreement contains customary representations, warranties and agreements by the Company as well as customary conditions to closing. The foregoing descriptions of the Underwriting Agreement and the Subscription Agreement are not complete and do not purport to be a complete description of the rights and obligations of the parties thereunder, and are qualified in their entirety by reference to the Underwriting Agreement and the Subscription Agreement that are filed as Exhibits 1.1 and 1.2, respectively, to this Report on Form 6-K (the “Report”) and are incorporated by reference herein.

    Copies of the opinions of Vischer AG relating to the validity of the issuance and sale of ordinary shares in the Underwritten Offering and Direct Offering are attached as Exhibits 5.1 and 5.2, respectively, to this Report and are incorporated by reference herein.

    On October 30, 2025, the Company issued a press release announcing the pricing of the Offerings. A copy of this press release is filed as Exhibit 99.1 to this Report and is incorporated by reference herein.

    This Report shall not constitute an offer to sell or the solicitation of an offer to buy the securities discussed herein, nor shall there be any offer, solicitation, or sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

    The information contained in this Report, including Exhibits 1.1, 1.2, 5.1 and 5.2 hereto but excluding Exhibit 99.1, is hereby incorporated by reference into the Company’s Registration Statement on Form S-8 (File No. 333-271938) and Registration Statements on Form F-3, as amended (File Nos. 333-278409, 333-271063 and 333-281798).


    EXHIBIT INDEX

     

    Exhibit    Description
     1.1    Underwriting Agreement, dated as of October  29, 2025, among the Company, J.P. Morgan Securities LLC , Leerink Partners LLC and Pareto Securities AB, as representatives of the several underwriters named therein.
     1.2    Form of Subscription Agreement, dated as of October 29, 2025.
     5.1    Opinion of Vischer AG, dated October 31, 2025
     5.2    Opinion of Vischer AG, dated October 31, 2025
    99.1    Press Release dated October 30, 2025.


    Forward-Looking Statements

    Statements in this Report that are not strictly historical in nature, including statements regarding the Company’s expectations with respect to the closing of the Offerings, are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including market risks and uncertainties and risks relating to the satisfaction of customary closing conditions for the Offerings. For a discussion of these and other factors, please refer to the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”), including the Company’s Annual Report on Form 20-F for the year ended December 31, 2024 under the caption “Risk Factors” and its subsequent reports filed with the SEC. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of this Report. The Company undertakes no obligation to publicly update or revise the information in this Report, including any forward-looking statements, except as may be required by law.


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

        OCULIS HOLDING AG
    Date: October 31, 2025     By:   /s/ Sylvia Cheung
         

    Sylvia Cheung

    Chief Financial Officer

    Get the next $OCS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OCS

    DatePrice TargetRatingAnalyst
    8/27/2025$36.00Buy
    Needham
    12/5/2023$30.00Buy
    Chardan Capital Markets
    10/5/2023$35.00Buy
    Stifel
    6/14/2023$22.00Buy
    BofA Securities
    6/12/2023$28.00Buy
    H.C. Wainwright
    6/8/2023$58.00Outperform
    Robert W. Baird
    5/10/2023$23.00Buy
    Pareto
    4/28/2023$27.00Outperform
    Wedbush
    More analyst ratings

    $OCS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Oculis Announces Oversubscribed $110 Million Financing to Accelerate Privosegtor Development

    ZUG, Switzerland, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS, XICE: OCS)) ("Oculis" or the "Company"), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today announced the pricing of offerings of an aggregate of 5,432,098 of its ordinary shares, CHF 0.01 nominal value per share, at a price of $20.25 per share for total gross proceeds of $110 million before deducting underwriting discounts and commissions and offering expenses. In connection with the Underwritten Offering, the Company has granted the underwriters a 30-day option to purchase up to an additional 703,

    10/30/25 4:30:29 AM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oculis to Spotlight Transformative Late-Stage Pipeline at Eyecelerator and AAO 2025

    ZUG, Switzerland, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), a global biopharmaceutical company focused on developing innovations for ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced that Oculis' innovative late-stage pipeline will be highlighted at Eyecelerator and at the American Academy of Ophthalmology (AAO) Annual Meeting. At Eyecelerator, Riad Sherif, MD, Oculis' Chief Executive Officer, will provide an update on the Company's innovative late-stage pipeline. Featured updates will include the acceleration of Privosegtor into registrational trials for acute optic neuritis and non-arteritic anterior ischemi

    10/14/25 4:00:00 AM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oculis Accelerates Privosegtor into Registrational Trials in Acute Optic Neuritis, Pioneering the Path for a Potential First-in-class Neuroprotective Therapy

    Successful meeting with FDA enables advancement into pivotal development with Privosegtor in Acute Optic Neuritis (AON) and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) Oculis will launch the PIONEER Program, which includes multiple global trials intended to support registrations in AON and NAION Company to host conference call and webcast at 8:30 AM ET today ZUG, Switzerland, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), a global biopharmaceutical company focused on innovations addressing neuro-ophthalmic diseases with significant unmet medical needs, today announces the advancement of Privosegtor into a registrational program for neuro-ophtha

    10/6/25 4:07:00 AM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OCS
    SEC Filings

    View All

    SEC Form 424B5 filed by Oculis Holding AG

    424B5 - Oculis Holding AG (0001953530) (Filer)

    10/31/25 5:25:38 PM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Oculis Holding AG

    424B5 - Oculis Holding AG (0001953530) (Filer)

    10/31/25 5:20:42 PM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Oculis Holding AG

    6-K - Oculis Holding AG (0001953530) (Filer)

    10/31/25 4:55:55 PM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OCS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Oculis Holding AG

    SC 13G - Oculis Holding AG (0001953530) (Subject)

    12/9/24 9:43:55 PM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Oculis Holding AG

    SC 13G/A - Oculis Holding AG (0001953530) (Subject)

    11/7/24 4:15:49 PM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OCS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Needham initiated coverage on Oculis Holding AG with a new price target

    Needham initiated coverage of Oculis Holding AG with a rating of Buy and set a new price target of $36.00

    8/27/25 8:25:52 AM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chardan Capital Markets initiated coverage on Oculis Holding AG with a new price target

    Chardan Capital Markets initiated coverage of Oculis Holding AG with a rating of Buy and set a new price target of $30.00

    12/5/23 8:03:01 AM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stifel initiated coverage on Oculis Holding AG with a new price target

    Stifel initiated coverage of Oculis Holding AG with a rating of Buy and set a new price target of $35.00

    10/5/23 7:50:21 AM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OCS
    Leadership Updates

    Live Leadership Updates

    View All

    Oculis Appoints Mark Kupersmith, M.D., and Sebastian Wolf, M.D., Ph.D., World-Renowned Neuro-Ophthalmology and Retina Experts, as Chief Medical Advisors

    Mark Kupersmith, M.D. appointed as Chief Medical Advisor, Neuro-Ophthalmology, following positive Phase 2 ACUITY trial results with Privosegtor (OCS-05) in acute optic neuritis and initiation of multiple programs in neuro-ophthalmologySebastian Wolf, M.D., Ph.D. appointed as Chief Medical Advisor, Ophthalmology, following the material advancement in retina programs with recent enrollment completion of Phase 3 DIAMOND trials of OCS-01 eye drops in diabetic macular edema and positive Phase 2 ACUITY trial results with Privosegtor (OCS-05) in acute optic neuritis ZUG, Switzerland, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), a global biopharmaceutical company f

    8/25/25 4:00:00 AM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oculis Publishes Invitation to the Annual General Meeting

    ZUG, Switzerland, May 09, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), today published the invitation to the 2025 Annual General Meeting, which will be held on June 4, 2025 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland, at 3:00 p.m. CEST / 9:00 a.m. EDT. The 2025 Annual General Meeting will be held in-person and broadcast. To join the broadcast, please use the following link. Information pertaining to the 2025 Annual General Meeting, including meeting materials, can be accessed on the Oculis website here. Oculis will host a virtual information session for all shareholders on May 19, 2025 from 4:00 to 5:00 p.m. CEST / 10:00 to 11:00 a.m. EDT, during

    5/9/25 4:05:00 PM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board

    Virometix AG, a privately held Swiss biotechnology company developing a new generation of fully synthetic vaccines to generate targeted and protective immune responses against infectious diseases and cancer today announces the appointment of Christina Ackermann as Chairwoman and Tim Ramdeen as a new member of its Board of Directors. Ms. Ackermann brings over 27 years of legal and management experience within the healthcare industries. Mr. Ramdeen has nearly a decade of experience in private equity, hedge fund investing, and capital markets. Christina Ackermann and Tim Ramdeen have led clinical and commercial companies through product development, growth, and commercialization while raising

    10/8/24 5:00:00 AM ET
    $ENTO
    $OCS
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OCS
    Financials

    Live finance-specific insights

    View All

    Oculis Accelerates Privosegtor into Registrational Trials in Acute Optic Neuritis, Pioneering the Path for a Potential First-in-class Neuroprotective Therapy

    Successful meeting with FDA enables advancement into pivotal development with Privosegtor in Acute Optic Neuritis (AON) and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) Oculis will launch the PIONEER Program, which includes multiple global trials intended to support registrations in AON and NAION Company to host conference call and webcast at 8:30 AM ET today ZUG, Switzerland, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), a global biopharmaceutical company focused on innovations addressing neuro-ophthalmic diseases with significant unmet medical needs, today announces the advancement of Privosegtor into a registrational program for neuro-ophtha

    10/6/25 4:07:00 AM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oculis Announces Positive Top Line Results from DIAMOND Stage 1 Phase 3 Trial in Diabetic Macular Edema with OCS-01 Eye Drops

    DIAMOND trial in Diabetic Macular Edema (DME) with topical OCS-01 met its stage 1 objective of validating the loading and maintenance dosing regimen designed to optimize OCS-01 efficacy potential with robust statistical significancePrimary efficacy endpoint of mean change in Best Corrected Visual Acuity (BCVA) versus baseline at Week 6 showed statistically significant increase in visual acuity in the OCS-01 arm compared to vehicle armStatistically significant secondary endpoints showed higher percentage of patients achieving ≥15-letter improvement in BCVA and better improvement in retinal thickness in the OCS-01 arm versus vehicle armOCS-01 was well-tolerated with no unexpected adverse event

    5/22/23 6:30:00 AM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oculis to Host Conference Call on April 13, 2023 to Discuss Late-Stage Pipeline and Near-Term Clinical Milestones

    ZUG, Switzerland and BOSTON, April 04, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announces that it will host a virtual conference call and webcast to present an overview of its late-stage pipeline and discuss expected near-term clinical milestones on Thursday, April 13 from 8:00am-9:00am ET / 13:00-14:00 BST / 14:00-15:00 CET. Oculis is focused on becoming a leading global ophthalmic biopharmaceutical company with product candidates to address areas of significant medical needs, including diabetic macular edema (DME), dry eye disease (DED), and neuro-retina indica

    4/4/23 7:00:00 AM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care